Literature DB >> 19657612

[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].

Bernhard Ludvik1, Helmut Brath, Thomas Wascher, Hermann Toplak.   

Abstract

Between 5 and 10% of the European population suffers from diabetes, and its prevalence is constantly rising, in Austria like in other countries. The main goals in the treatment of diabetes mellitus are the prevention of complications and organ damage, the prevention of severe hypo- and hyperglycaemia and the preservation of quality of life. Many patients with type 2 diabetes become insulin-dependent in the course of their disease. The application of a long acting insulin or insulin analogue is the simplest way of initiating an insulin therapy and is in accordance with current guidelines. Current scientific evidence shows that the use of long acting insulin analogues for type 2 diabetes; which can no longer be sufficiently controlled with oral antidiabetic agents, is simple, safe and efficacious. Thus, this treatment option should be available without any restrictions to physicians and patients in order to facilitate the beginning of an insulin regime. This position paper summarises up the current evidence concerning this subject.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657612     DOI: 10.1007/s00508-009-1209-4

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  73 in total

1.  Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system.

Authors:  Xian Ling Wang; Ju Ming Lu; Chang Yu Pan; Yi Ming Mu; Jing Tao Dou; Jian Ming Ba; Xuemin Wang
Journal:  Diabetes Res Clin Pract       Date:  2006-09-15       Impact factor: 5.602

2.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

3.  Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

Authors:  T R Pieber; I Eugène-Jolchine; E Derobert
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

4.  Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.

Authors:  K Kølendorf; G P Ross; I Pavlic-Renar; G Perriello; A Philotheou; J Jendle; M-A Gall; S R Heller
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

5.  A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

Authors:  M Massi Benedetti; E Humburg; A Dressler; M Ziemen
Journal:  Horm Metab Res       Date:  2003-03       Impact factor: 2.936

6.  Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study.

Authors:  Robyn Houlden; Stuart Ross; Stewart Harris; Jean-Francois Yale; Luc Sauriol; Hertzel C Gerstein
Journal:  Diabetes Res Clin Pract       Date:  2007-05-09       Impact factor: 5.602

7.  Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.

Authors:  Hiroki Yokoyama; Junko Tada; Futayo Kamikawa; Sakiko Kanno; Yuki Yokota; Masae Kuramitsu
Journal:  Diabetes Res Clin Pract       Date:  2006-03-02       Impact factor: 5.602

8.  Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

Authors:  Reinhard G Bretzel; Ulrike Nuber; Wolfgang Landgraf; David R Owens; Clare Bradley; Thomas Linn
Journal:  Lancet       Date:  2008-03-29       Impact factor: 79.321

9.  Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

Authors:  G Papa; V Fedele; A Chiavetta; I Lorenti; C Leotta; S Luca; A M Rabuazzo; S Piro; C Alagona; L Spadaro; F Purrello; V Pezzino
Journal:  Acta Diabetol       Date:  2008-01-08       Impact factor: 4.280

10.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122

View more
  1 in total

1.  How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment.

Authors:  Baptist Gallwitz; Reinhard G Bretzel
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.